Lazarus Pharmaceuticals is a clinical-stage drug development company that identifies and advances therapies for diseases with unmet medical needs. Its two gastroenterology portfolio companies are pursuing treatments for functional gastrointestinal disease and a rare neonatal GI condition. Co-founders Alan Joslyn and Joseph Sanger bring decades of pharmaceutical development and commercial experience to the company’s asset-focused model.